Clinical Trials Browser

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06866262 2025-09-09

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03690986 2025-07-23

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Phase 1 Recruiting

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05361720 2025-07-23

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Phase 2 Recruiting

54 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04003649 2025-07-10

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Phase 1 Recruiting

60 enrolled

CNS

Glioblastoma

NCT04659343 2025-03-05

TDM for Optimized Outcome in Patients With mRCC.

Recruiting

200 enrolled

Genitourinary

Kidney Neoplasms, Drug-Related Side Effects and Adverse Reactions

Clinical Trials

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

SAMURAI

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

TDM for Optimized Outcome in Patients With mRCC.